BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Unusual case of plasmablastic non-Hodgkin's lymphoma located in the liver. First case reported in an AIDS patient.

Plasmablastic lymphoma is a rare and a relatively new entity that was first described in the jaws and the oral cavity of HIV-AIDS patients.

We report a case of plasmablastic lymphoma involving the liver in an AIDS patient.

Plasmablastic lymphoma is considered a diffuse large B-cell lymphoma with a unique phenotype and predilection for the oral cavity.

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Liver Cancer.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19841505.001).

[ISSN] 1665-2681

[Journal-full-title] Annals of hepatology

[ISO-abbreviation] Ann Hepatol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Mexico

[Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / Syndecan-1; 0 / interferon regulatory factor-4

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related lymphomas in Nigeria.

Aggressive non-Hodgkin's lymphoma (NHL), including primary central nervous system (CNS) lymphoma, lymphoblastic lymphoma and non-endemic Burkitt's lymphoma have been recognized as AIDS-defining cancers in most developed countries.

However, HIV/AIDS epidemics appear not to have been associated with higher incidence of lymphomas in Africa.

We therefore carried out this study to highlight the significance or otherwise of HIV/AIDS epidemics in the pathogenesis of lymphomas in a population of Nigerians with the disease.

Patients with a histological diagnosis of malignant chronic lymphoproliferative diseases {non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), Burkitt's lymphoma (BL) and Hodgkin lymphoma (HL)} at the Obafemi Awolowo University Teaching Hospitals' Complex, Ile-Ife from January 1993 to August 2008 were noted.

Those patients confirmed to be HIV/AIDS positive among the cohort with lymphomas were retrospectively studied using their clinical case notes.

A total of 391 patients were histologically confirmed to have lymphoma {NHL-109, (27.9%); CLL-76, (19.4%); BL-178, (45.5%) and HL-28, (7.2%)} during the study period.

Six of these, five males and one female, ages 24-60 (median = 37.5) years, had NHL while another three, all females (age 50 - 68 years; median = 56 years) had CLL.

Patients with NHL presented at advanced stage of the disease (at least clinical stage IIIb), and all those with CLL presented at stage C of the International Working Party Classification.

All the HIV-positive patients with NHL succumbed to the disease within one to three weeks of admission into the hospital.

The prevalence of AIDS-related lymphomas is 2.3% compared to 4.4% found in the general population.

However, it is interesting that no single case of AIDS-associated BL was seen, despite the fact that Burkitt's lymphoma is endemic in this part of the world.

[MeSH-major] Lymphoma, AIDS-Related / epidemiology

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20428636.001).

[ISSN] 1678-4391

[Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

[ISO-abbreviation] Braz J Infect Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] Brazil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Non-Hodgkin's lymphoma in the elderly.

The expansion of older population segments and the continuous increase in the incidence of non-Hodgkin's lymphoma (NHL) makes this group of neoplasms an important and growing problem.

Older NHL patients have increased risk of therapy-related toxicity as a result of age-related physiological changes and frequent co-morbidities.

The comprehensive geriatric assessment (CGA) is one multidisciplinary tool that has been applied successfully to older cancer patients and aids in identification of subjects who will or will not benefit from anti-neoplastic treatment.

Diffuse large B-cell lymphoma is an aggressive but potentially curable disease.

Highly selected individuals up to age 70 years may attain long-term survival benefit from autoHCT, although transplant-related mortality is higher than in younger patients.

[MeSH-major] Aging / physiology. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / physiopathology. Lymphoma, Non-Hodgkin / therapy

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Seniors' Health.

Hazardous Substances Data Bank. RITUXIMAB .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]

[Cites] Blood. 2008 Jun 15;111(12 ):5486-95 [18390837.001]

[Cites] Clin Pharmacokinet. 2003;42(9):779-91 [12882586.001]

[Cites] Semin Oncol. 2002 Feb;29(1S2):25-29 [28140088.001]

[Cites] Oncology (Williston Park). 2007 Aug;21(9):1104-10 [17910313.001]

[Cites] Clin Pharmacokinet. 1996 Jul;31(1):47-64 [8827399.001]

[Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]

[Cites] J Clin Oncol. 2007 Mar 1;25(7):787-92 [17228021.001]

[Cites] J Clin Oncol. 2001 Jan 15;19(2):389-97 [11208830.001]

[Cites] J Clin Oncol. 2004 Aug 1;22(15):3032-8 [15210738.001]

[Cites] Best Pract Res Clin Haematol. 2005 Mar;18(1):81-95 [15694186.001]

[Cites] Blood. 1990 Oct 1;76(7):1293-8 [2207307.001]

[Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]

[Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]

[Cites] Cancer. 2008 May 15;112(10):2228-32 [18338745.001]

[Cites] Eur J Haematol. 2008 Feb;80(2):127-32 [18005385.001]

[Cites] Crit Rev Oncol Hematol. 2008 Oct;68 Suppl 1:S1-8 [18752969.001]

[Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]

[Cites] Eur J Cancer. 2003 May;39(7):870-80 [12706355.001]

[Cites] J Clin Oncol. 2009 Jun 20;27(18):3036-43 [19414675.001]

[Cites] J Clin Oncol. 1995 Jul;13(7):1726-33 [7602362.001]

[Cites] J Clin Oncol. 2009 Aug 10;27(23):3822-9 [19581539.001]

[Cites] Blood. 2002 Sep 1;100(5):1559-65 [12176870.001]

[Cites] Curr Treat Options Oncol. 2006 Jul;7(4):285-94 [16916489.001]

[Cites] Lancet Oncol. 2006 May;7(5):357-9 [16648037.001]

[Cites] J Clin Oncol. 2004 Apr 15;22(8):1454-9 [15024027.001]

[Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]

[Cites] Oncology (Williston Park). 2007 Sep;21(10):1191-8; discussion 1198-1208, 1210 [17926798.001]

[Cites] Blood. 2005 May 15;105(10):3817-23 [15687232.001]

[Cites] Crit Rev Oncol Hematol. 2000 Feb;33(2):119-28 [10737373.001]

[Cites] Am J Geriatr Pharmacother. 2008 Aug;6(3):153-60 [18775390.001]

[Cites] Cancer Control. 2007 Jan;14(1):44-56 [17242670.001]

[Cites] Crit Rev Oncol Hematol. 2005 Sep;55(3):241-52 [16084735.001]

[Cites] Ann Oncol. 2007 Jul;18(7):1216-23 [17470451.001]

[Cites] J Clin Oncol. 2004 Nov 1;22(21):4302-11 [15381684.001]

[Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]

[Cites] Ann Oncol. 2009 Mar;20(3):520-5 [19074748.001]

[Cites] Semin Hematol. 1999 Apr;36(2):115-27 [10319380.001]

[Cites] J Clin Oncol. 2003 Nov 1;21(21):3918-27 [14517188.001]

[Cites] Br J Haematol. 2005 May;129(3):366-72 [15842660.001]

[Cites] Leuk Lymphoma. 2008;49 Suppl 1:43-51 [18821432.001]

[Cites] J Clin Oncol. 2007 Jul 20;25(21):3158-67 [17634496.001]

[Cites] Br J Haematol. 2009 May;145(3):344-9 [19245430.001]

[Cites] J Clin Oncol. 2004 Aug 1;22(15):2982-4 [15210737.001]

[Cites] Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 2:S43-9 [18284715.001]

[Cites] Bull Cancer. 2008 May 28;95 FMC Onco:F79-83 [18511372.001]

[Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]

[Cites] Leuk Lymphoma. 1999 Jul;34(3-4):273-85 [10439364.001]

[Cites] J Clin Oncol. 2008 Jan 10;26(2):204-10 [18182663.001]

[Cites] Am J Health Syst Pharm. 2007 Mar 15;64(6):652-60 [17353576.001]

[Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]

[Cites] N Engl J Med. 1992 Oct 22;327(17):1209-15 [1406793.001]

[Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]

[Cites] J Clin Oncol. 2009 Mar 10;27(8):1209-13 [19188674.001]

[Cites] J Clin Oncol. 2005 Jul 1;23(19):4390-8 [15994148.001]

[Cites] J Clin Oncol. 2000 Apr;18(7):1412-22 [10735888.001]

[Cites] Aging Clin Exp Res. 2005 Jun;17(3):181-5 [16110729.001]

[Cites] J Clin Oncol. 2008 Sep 20;26(27):4473-9 [18626004.001]

[Cites] Leukemia. 2007 Nov;21(11):2324-31 [17637813.001]

[Cites] Bone Marrow Transplant. 2000 May;25(9):957-64 [10800063.001]

[Cites] J Immunol. 2009 Jul 1;183(1):749-58 [19535640.001]

[Cites] J Clin Oncol. 2006 May 1;24(13):2105-12 [16606971.001]

[Cites] J Clin Oncol. 2008 Oct 1;26(28):4579-86 [18662969.001]

[Cites] Cancer. 1983 Aug 1;52(3):393-8 [6344979.001]

[Cites] J Clin Oncol. 2009 Apr 1;27(10):1607-14 [19255334.001]

[Cites] Clin Geriatr Med. 1997 May;13(2):251-63 [9115450.001]

[Cites] J Clin Oncol. 1997 Aug;15(8):2945-53 [9256139.001]

[Cites] N Engl J Med. 1993 Sep 30;329(14):1046 [8366915.001]

[Cites] Biol Blood Marrow Transplant. 2008 Dec;14(12):1323-33 [19041053.001]

[Cites] Cochrane Database Syst Rev. 2008 Oct 08;(4):CD003189 [18843642.001]

[Cites] J Clin Oncol. 2006 Aug 20;24(24):3880-6 [16864854.001]

[Cites] J Clin Oncol. 2005 Mar 20;23(9):1984-92 [15668467.001]

[Cites] Blood. 2006 Dec 15;108(13):4003-8 [16946304.001]

[Cites] Haematologica. 2002 Jan;87(1):33-43 [11801463.001]

[Cites] Blood. 2005 Apr 1;105(7):2677-84 [15591112.001]

[Cites] Br J Haematol. 2008 Jun;142(2):149-65 [18410453.001]

[Cites] J Clin Oncol. 2005 Aug 10;23(23):5347-56 [15983389.001]

[Cites] J Clin Oncol. 2003 Sep 1;21(17):3214-9 [12874269.001]

[Cites] Cancer. 1976 Oct;38(4):1484-93 [791473.001]

[Cites] J Clin Oncol. 1986 Mar;4(3):295-305 [3512783.001]

[Cites] Hematol Oncol. 1989 Sep-Oct;7(5):365-80 [2670728.001]

[Cites] Ann Hematol. 2001 Jul;80(7):398-405 [11529465.001]

[Cites] Blood. 2003 May 15;101(10):3840-8 [12531794.001]

[Cites] J Am Geriatr Soc. 2001 Dec;49(12):1691-9 [11844005.001]

[Cites] Br J Haematol. 2007 Jan;136(2):191-202 [17073892.001]

[Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]

[Cites] N Engl J Med. 2005 Mar 24;352(12):1197-205 [15788496.001]

[Cites] J Clin Oncol. 2007 Jun 20;25(18):2554-9 [17515573.001]

[Cites] Radiother Oncol. 1995 Sep;36(3):167-71 [8532901.001]

[Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]

[Cites] Eur J Cancer. 2006 Oct;42(15):2433-53 [16750358.001]

[Cites] Clin Lymphoma. 2001 Jun;2(1):47-56 [11707870.001]

[Cites] Leuk Lymphoma. 2008;49 Suppl 1:59-66 [18821434.001]

[Cites] Blood. 2004 Oct 15;104(8):2269-71 [15166030.001]

[Cites] Blood. 1994 Oct 15;84(8):2726-32 [7919385.001]

[Cites] Semin Oncol. 1993 Feb;20(1):43-9 [8475409.001]

[Cites] Cancer. 2004 Oct 15;101(8):1835-42 [15386331.001]

[Cites] Ann Oncol. 2007 Jan;18(1):116-21 [16971665.001]

[Cites] Br J Haematol. 2003 Aug;122(3):413-23 [12877668.001]

[Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]

[Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]

[Cites] Blood. 1999 Jul 1;94(1):33-8 [10381495.001]

[Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]

[Cites] Ann Oncol. 2006 Sep;17 (9):1418-23 [16766582.001]

[Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6 [2456618.001]

[Cites] N Engl J Med. 1998 Sep 24;339(13):900-5 [9744975.001]

[Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1219-27 [11728680.001]

[Cites] Expert Rev Anticancer Ther. 2008 Oct;8(10):1651-8 [18925856.001]

[Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]

[Cites] Ann Oncol. 2008 Jul;19(7):1327-30 [18349031.001]

[Cites] J Clin Oncol. 2005 Feb 1;23(4):667-75 [15613697.001]

[Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]

[Cites] Ann Intern Med. 2002 Jan 15;136(2):144-52 [11790067.001]

[Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):928-34 [16243446.001]

[Cites] Eur J Cancer. 2008 Mar;44(4):579-87 [18242077.001]

[Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]

[Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301 [16985248.001]

[Cites] Cancer. 2003 Dec 15;98(12):2630-5 [14669282.001]

[Cites] Cancer Invest. 2007 Dec;25(8):766-75 [18058474.001]

[Cites] J Clin Oncol. 2008 Jul 1;26(19):3159-65 [18591554.001]

[Cites] Ann Oncol. 2008 Jun;19 Suppl 4:iv60-2 [18519407.001]

[Cites] Cancer Control. 2003 Nov-Dec;10(6):487-99 [14652525.001]

[Cites] J Clin Oncol. 2003 Jun 15;21(12):2407-14 [12805341.001]

[Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]

[Cites] Cancer Control. 1996 Oct;3(5 Suppl 1):5-14 [10765230.001]

[Cites] J Clin Oncol. 1997 Mar;15(3):1110-7 [9060552.001]

[Cites] Blood. 2004 Nov 1;104(9):2667-74 [15238420.001]

[Cites] J Natl Cancer Inst. 2007 May 2;99(9):706-14 [17470738.001]

[Cites] Bone Marrow Transplant. 2001 Mar;27(6):593-9 [11319588.001]

[Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]

[Cites] Nephron. 1976;16(1):31-41 [1244564.001]

[Cites] J Clin Oncol. 2005 Feb 20;23(6):1088-95 [15657401.001]

[Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]

[Cites] J Clin Oncol. 2006 Apr 1;24(10):1582-9 [16575009.001]

[Cites] Lancet. 2009 Oct 31;374(9700):1512-20 [19767089.001]

[Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]

[Cites] J Clin Oncol. 1998 Jan;16(1):13-8 [9440717.001]

[Cites] J Clin Oncol. 2005 Oct 1;23(28):7013-23 [16145068.001]

[Cites] J Clin Oncol. 2005 May 20;23(15):3383-9 [15908650.001]

[Cites] Ann Oncol. 1995 Mar;6(3):257-62 [7612491.001]

[Cites] J Clin Oncol. 1996 Apr;14(4):1282-90 [8648385.001]

[Cites] Clin Cancer Res. 2008 Jan 1;14(1):309-17 [18172283.001]

[Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]

[Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):1037-49, x-xi [18954750.001]

[Cites] Blood. 1997 May 1;89(9):3129-35 [9129015.001]

[Cites] J Clin Oncol. 1995 Oct;13(10):2530-9 [7595704.001]

[Cites] Semin Oncol. 2003 Feb;30(1S2):9-15 [28140221.001]

[Cites] J Clin Oncol. 2009 Mar 10;27(8):1202-8 [19204203.001]

[Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]

[Cites] Cancer Control. 2007 Jan;14(1):7-12 [17242666.001]

[Cites] J Clin Oncol. 1998 Jul;16(7):2352-8 [9667250.001]

[Cites] Leuk Lymphoma. 2009 Jan;50(1):47-53 [19152172.001]

[Cites] Cancer. 2005 Nov 1;104(9):1998-2005 [16206252.001]

[Cites] Ann Hematol. 2007 Feb;86(2):95-100 [17031689.001]

[Cites] Nat Rev Cancer. 2009 Sep;9(9):675-81 [19701243.001]

[Cites] Curr Opin Oncol. 2008 Sep;20(5):502-8 [19106651.001]

[Cites] Bone Marrow Transplant. 2007 Nov;40(10):973-8 [17873917.001]

[Cites] Cancer. 1997 Oct 1;80(7):1302-10 [9317183.001]

[Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]

[Cites] Haematologica. 2008 Dec;93(12):1837-42 [18838474.001]

[Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]

[Cites] Ann Intern Med. 1990 May 1;112(9):699-706 [2334082.001]

[Cites] Drugs Aging. 2003;20(10):737-59 [12875610.001]

[Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]

[Cites] J Clin Oncol. 2002 Jan 15;20(2):494-502 [11786579.001]

[Cites] Eur J Cancer. 1998 Feb;34(3):329-36 [9640217.001]

[Cites] Gerontology. 1999 Sep-Oct;45(5):243-53 [10460985.001]

[Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]

[Cites] Haematologica. 2006 Jan;91(1):11-6 [16434365.001]

[Cites] J Clin Oncol. 2003 Aug 15;21(16):3051-9 [12837807.001]

[Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]

[Cites] Ann Oncol. 1994;5 Suppl 2:67-71 [7515649.001]

[Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]

[Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]

[Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):863-82, viii [18954741.001]

[Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]

[Cites] J Clin Oncol. 1998 Jan;16(1):27-34 [9440719.001]

[Cites] Semin Radiat Oncol. 2007 Jul;17(3):169-75 [17591563.001]

[Cites] N Engl J Med. 2008 Aug 7;359(6):613-26 [18687642.001]

[Cites] Blood. 2006 Oct 15;108(8):2540-4 [16835383.001]

[Cites] J Clin Oncol. 2009 Mar 20;27(9):1492-501 [19224851.001]

[Cites] J Clin Oncol. 2003 Jan 1;21(1):5-15 [12506163.001]

[Cites] J Clin Oncol. 2004 Apr 15;22(8):1469-79 [15084620.001]

[Cites] Ann Oncol. 1997 Jul;8(7):675-80 [9296221.001]

[Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]

[Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]

[Cites] Blood. 2008 Oct 1;112(7):2687-93 [18625886.001]

[Cites] Blood. 2001 Jan 1;97(1):101-6 [11133748.001]

[Cites] Blood. 2002 Jun 15;99(12 ):4336-42 [12036859.001]

[Cites] Lancet Neurol. 2009 Jun;8(6):581-92 [19446277.001]

[Cites] Blood Rev. 2009 May;23(3):137-42 [18951668.001]

[Cites] Cancer Invest. 2006 Oct;24(6):593-600 [16982464.001]

[Cites] Cancer. 2006 Oct 1;107(7):1530-41 [16933332.001]

[Cites] Cancer Control. 2002 May-Jun;9(3):203-11 [12060818.001]

[Cites] Blood. 2001 Jan 15;97(2):404-9 [11154216.001]

[Cites] J Clin Oncol. 2003 Aug 15;21(16):3041-50 [12915593.001]

[Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]

[Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]

[Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]

[Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]

[Cites] J Clin Oncol. 2008 Mar 20;26(9):1544-52 [18285605.001]

[Cites] J Clin Oncol. 2002 Feb 1;20(3):770-5 [11821460.001]

[Cites] Lancet Oncol. 2008 Feb;9(2):105-16 [18226581.001]

[Cites] J Clin Oncol. 1998 Dec;16(12):3803-9 [9850025.001]

[Cites] Blood. 2009 Apr 23;113(17):3896-902 [19144985.001]

[Cites] J Clin Oncol. 2009 Feb 1;27(4):511-8 [19075279.001]

[Cites] J Clin Oncol. 2008 Oct 20;26(30):4952-7 [18606983.001]

[Cites] Blood. 2009 Apr 30;113(18):4144-52 [19168784.001]

[Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]

(PMID = 20210368.001).

[ISSN] 1179-1969

[Journal-full-title] Drugs & aging

[ISO-abbreviation] Drugs Aging

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] New Zealand

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Elevated expression of activation induced cytidine deaminase in peripheral blood mononuclear cells precedes AIDS-NHL diagnosis.

Non-Hodgkin's B cell lymphoma (NHL) is a common cancer in HIV infection.

Many NHL are thought to result from errors in class switch recombination and/or somatic hypermutation, processes that occur in germinal center B cells, and require the activity of activation induced cytidine deaminase (AID).

Since NHL is a common cancer in HIV infection, and expression of AID could contribute to the development of NHL, we hypothesized that AID expression would be elevated in those who went on to develop AIDS-associated NHL (AIDS-NHL).

AID mRNA levels were measured by TaqMan RT-PCR in peripheral blood mononuclear cells, obtained prior to AIDS-NHL diagnosis, from 16 HIV-infected subjects who developed AIDS-NHL, and from control subjects (AIDS but no NHL, and HIV-negative subjects).

PBMC AID expression was markedly elevated in those who developed AIDS-NHL, when compared to AIDS and HIV-negative controls.

Additionally, AID expression was seen to differ depending on NHL subtype, with the highest levels of expression seen in those who developed Burkitt's lymphoma.

[MeSH-major] B-Lymphocytes / enzymology. Cytidine Deaminase / genetics. Gene Expression Regulation, Viral. Lymphoma, AIDS-Related / enzymology. Lymphoma, B-Cell / enzymology

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18090274.001).

[ISSN] 0269-9370

[Journal-full-title] AIDS (London, England)

[ISO-abbreviation] AIDS

[Language] eng

[Grant] United States / NIAID NIH HHS / AI / AI28697; United States / NCI NIH HHS / CA / CA57152; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888

[Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / RNA, Viral; EC 3.5.4.5 / Cytidine Deaminase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection.

Patients with Multicentric Castleman Disease and HHV-8-related lymphoma diagnosed and treated from April 1987 to June 2004 were included in the study.

Nine patients with Multicentric Castleman disease, and 16 with HHV-8-related lymphomas (13 primary effusion lymphomas and 3 solid lymphomas), were diagnosed and treated out of 327 HIV-related non-Hodgkin's lymphomas.

Nine patients with primary effusion lymphoma were treated with a CHOP-like regimen (Cyclophosphamide, Prednisone anthracyclines, Vinca alkaloids, Bleomycin, Etoposide) and HAART; 1 with etoposide and HAART, 1 with HAART alone.

The patients with solid lymphoma underwent CHOP-like chemotherapy.

Patients with Multicentric Castleman disease showed lower median values of HHV-8 viral load and longer overall survival compared with HHV-8-related lymphomas.

In the univariate analysis, HHV-8-related lymphoma, HHV-8 viral load >40,000 cp/ml and performance status >2 were associated with an increased risk of death.

Multivariate analysis confirmed the diagnosis of lymphoma as an independent predictor of shorter survival.

[MeSH-major] HIV Infections / complications. Herpesviridae Infections / complications. Herpesvirus 8, Human / physiology. Lymphoma, AIDS-Related / drug therapy. Lymphoproliferative Disorders / complications. Viral Load

[MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. DNA, Viral / blood. Female. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / diagnosis. Giant Lymph Node Hyperplasia / drug therapy. Giant Lymph Node Hyperplasia / virology. Humans. Lymphoma / complications. Lymphoma / diagnosis. Lymphoma / drug therapy. Lymphoma / virology. Lymphoma, Primary Effusion / complications. Lymphoma, Primary Effusion / diagnosis. Lymphoma, Primary Effusion / drug therapy. Lymphoma, Primary Effusion / virology. Male. Middle Aged. Prognosis. Survival Analysis. Survival Rate. Treatment Outcome. Young Adult

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2009 Wiley-Liss, Inc.

(PMID = 19319955.001).

[ISSN] 1096-9071

[Journal-full-title] Journal of medical virology

[ISO-abbreviation] J. Med. Virol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The major histocompatibility complex conserved extended haplotype 8.1 in AIDS-related non-Hodgkin lymphoma.

BACKGROUND: Two single nucleotide polymorphisms (SNPs) in adjacent genes, lymphotoxin alpha (LTA +252G, rs909253 A>G) and tumor necrosis factor (TNF -308A, rs1800629 G>A), form the G-A haplotype repeatedly associated with increased risk of non-Hodgkin lymphoma (NHL) in individuals uninfected with HIV-1.

OBJECTIVE: We aimed to determine whether the reported association of the G-A haplotype of LTA-TNF with non-AIDS NHL also occurs with AIDS-related NHL.

METHODS: SNPs in LTA and TNF and in 6 other genes nearby were typed in 140 non-Hispanic European American pairs of AIDS-NHL cases and matched controls selected from HIV-infected men in the Multicenter AIDS Cohort Study.

RESULTS: The G-A haplotype and a 4-SNP haplotype in the neighboring gene cluster (rs537160 (A) rs1270942 (G), rs2072633 (A), and rs6467 (C)) were associated with AIDS-NHL (odds ratio = 2.7, 95% confidence interval: 1.5 to 4.8, P = 0.0009; and odds ratio = 3.2, 95% confidence interval: 1.6 to 6.6, P = 0.0008; respectively).

CONCLUSION: The CEH 8.1-specific haplotype association of MHC class III variants with AIDS-NHL closely resembles that observed for non-AIDS NHL.

Corroboration of an MHC determinant of AIDS and non-AIDS NHL alike would imply an important pathogenetic mechanism common to both.

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Curr Opin Pharmacol. 2004 Aug;4(4):314-20 [15251122.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195-9 [9096369.001]

[Cites] Lancet. 1990 Apr 21;335(8695):927-30 [1970024.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] Hum Immunol. 1992 Aug;34(4):242-52 [1464552.001]

[Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]

[Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]

[Cites] Biometrics. 1999 Dec;55(4):997-1004 [11315092.001]

[Cites] Eur J Cancer. 2001 Jul;37(10):1316-9 [11423263.001]

[Cites] Hum Hered. 2002;53(2):79-91 [12037407.001]

[Cites] Science. 2002 Jun 21;296(5576):2225-9 [12029063.001]

[Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]

[Cites] Blood. 2002 Oct 15;100(8):3037-40 [12351419.001]

[Cites] Genome Res. 2004 Jun;14(6):1176-87 [15140828.001]

[Cites] J Hered. 1995 Sep-Oct;86(5):409-11 [7560877.001]

[Cites] Mol Biol Evol. 1995 Sep;12(5):921-7 [7476138.001]

[Cites] Transplantation. 1995 Nov 27;60(10):1113-7 [7482718.001]

[Cites] J Neuroimmunol. 1995 Dec 31;63(2):143-7 [8550811.001]

[Cites] Clin Exp Immunol. 1996 Mar;103(3):391-6 [8608636.001]

[Cites] J Neuroimmunol. 1997 Feb;72(2):149-53 [9042107.001]

[Cites] Blood. 1998 May 15;91(10):3574-81 [9572991.001]

[Cites] Clin Exp Immunol. 1998 Sep;113(3):401-6 [9737669.001]

[Cites] Immunol Rev. 1999 Feb;167:257-74 [10319267.001]

[Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]

[Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]

[Cites] J Med Virol. 2005 Jul;76(3):302-10 [15902698.001]

[Cites] Nat Genet. 2005 Nov;37(11):1217-23 [16244653.001]

[Cites] J Clin Oncol. 2005 Nov 20;23(33):8414-21 [16293872.001]

[Cites] J Infect Dis. 2006 Jan 1;193(1):16-26 [16323127.001]

[Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]

[Cites] Eur J Cancer. 2006 Apr;42(6):745-50 [16517151.001]

[Cites] Br J Haematol. 2006 May;133(3):293-300 [16643431.001]

[Cites] Diabetes. 2006 May;55(5):1265-9 [16644681.001]

[Cites] Genomics. 2006 May;87(5):561-71 [16434165.001]

[Cites] Blood. 2006 May 15;107(10):4101-8 [16449530.001]

[Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W621-5 [16845085.001]

[Cites] Cancer Res. 2006 Oct 1;66(19):9771-80 [17018637.001]

[Cites] Genes Chromosomes Cancer. 2007 May;46(5):500-7 [17311253.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8 [17337643.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]

[Cites] Cancer Res. 2007 May 15;67(10):5042-54 [17510437.001]

[Cites] Tissue Antigens. 2008 Jan;71(1):16-26 [17971052.001]

[Cites] Immunogenetics. 2008 Jan;60(1):1-18 [18193213.001]

[Cites] Int J Immunogenet. 2008 Jun;35(3):179-92 [18397301.001]

[Cites] Carcinogenesis. 2007 Mar;28(3):704-12 [17056605.001]

[Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]

(PMID = 19654554.001).

[ISSN] 1944-7884

[Journal-full-title] Journal of acquired immune deficiency syndromes (1999)

[ISO-abbreviation] J. Acquir. Immune Defic. Syndr.

[Language] ENG

[Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NCI NIH HHS / CA / R01 CA073475-03; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NCI NIH HHS / CA / R01 CA073475; United States / NIAID NIH HHS / AI / UO1-AI-37984; United States / NCI NIH HHS / CA / R01 CA106168-01A1; United States / NCI NIH HHS / CA / CA106168-01A1; United States / NCI NIH HHS / CA / P50-CA96888; United States / NCI NIH HHS / CA / R01 CA106168; United States / NCI NIH HHS / CA / CA073475-03; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NCI NIH HHS / CA / P50 CA096888-01; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NIAID NIH HHS / AI / P30 AI045008; United States / NIAID NIH HHS / AI / UO1-AI-35040,; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NIAID NIH HHS / AI / P30 AI045008-01; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NCI NIH HHS / CA / R01-CA106168; United States / NIAID NIH HHS / AI / AI045008-01; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NCI NIH HHS / CA / CA096888-01; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NCI NIH HHS / CA / P50 CA096888; United States / NIAID NIH HHS / AI / P30 AI 045008; United States / NIAID NIH HHS / AI / UO1-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NCI NIH HHS / CA / R01-CA73475

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / HLA Antigens; 0 / Lymphotoxin-alpha; 0 / Tumor Necrosis Factor-alpha

[Other-IDs] NLM/ NIHMS250460; NLM/ PMC3015185

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Non-Hodgkin's lymphoma as a rare manifestation of immune reconstitution disease in HIV-1 positive patients.

IRS can develop within weeks to months after cART is commenced and the time is related to the type of the disease.

There are but scant reports concerning IRS-NHL (non-Hodgkin's lymphoma) in HIV-1 positive subjects.

We observed 4 (33%) cases of IRS-NHL out of 12 patients in whom NHL was diagnosed.

The diagnosis of NHL was established at a mean time of 36 weeks after cART was introduced and 20 weeks after the CD4 T cell increase was achieved.

This may indicate that the immune reconstitution as a result of cART was a predisposing factor for the development of NHL in our patients.

IRS-NHL should be suspected in any case of lymphadenopathy, generalized or limited to the abdomen or periphery, which develops after immune recovery due to potent cART within a few months.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17060896.001).

[ISSN] 1732-2693

[Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)

[ISO-abbreviation] Postepy Hig Med Dosw (Online)

[Language] ENG

[Publication-type] Case Reports; Journal Article

[Publication-country] Poland

[Chemical-registry-number] 0 / Anti-HIV Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hematopoietic cell transplantation in non-Hodgkin's lymphoma.

OBJECTIVE: To explore the role and outcomes using hematopoietic cell transplantation (HCT) as a treatment option with aggressive, follicular, mantle, T-cell, and HIV related non-Hodgkin's lymphoma (NHL).

CONCLUSION: High-dose chemotherapy and/or radiation therapy followed by HCT has been used to overcome resistance to standard-dose therapy and has been explored over the past 40 years and has shown long-term survival of approximately 10% to 50% in patients with relapsed or refractory lymphoma.

[MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy

[MeSH-minor] Humans. Lymphoma, AIDS-Related / nursing. Lymphoma, AIDS-Related / therapy. Lymphoma, Follicular / nursing. Lymphoma, Follicular / therapy. Lymphoma, Mantle-Cell / nursing. Lymphoma, Mantle-Cell / therapy. Lymphoma, T-Cell / nursing. Lymphoma, T-Cell / therapy. Transplantation Conditioning / adverse effects. Transplantation Conditioning / nursing

Genetic Alliance. consumer health - Transplantation.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16720233.001).

[ISSN] 0749-2081

[Journal-full-title] Seminars in oncology nursing

[ISO-abbreviation] Semin Oncol Nurs

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 46

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma.

We previously observed a loss of Epstein-Barr virus (EBV)-specific CD8+ T cells in subjects progressing to EBV-related non-Hodgkin lymphoma (NHL), correlating with loss of CD4+ T cells.

The aim of the present study was to determine the role of EBV-specific CD4+ T cells in the development of NHL during chronic HIV infection.

To this end, CD4+ and CD8+ memory T cells, capable of both proliferation and subsequent interferon gamma (IFNgamma) production, directed against a latent (Epstein-Barr virus nuclear antigen 1 [EBNA1]) and a lytic (BamH fragment Z left frame 1 [BZLF1]) EBV antigen were studied longitudinally in 9 progressors to NHL, 4 progressors to non-EBV-related AIDS, and 4 slow progressors to AIDS.

However, whereas latent antigen EBNA1-specific CD4+ T cells were lost well before diagnosis in all subjects who developed an AIDS-related NHL (and EBNA1-specific CD8+ T cells were significantly lower compared with the other groups), these cells were better preserved in progressors to non-EBV-related disease and slow progressors.

Loss of EBNA1-specific T-cell immunity thus might be important for progression to NHL.

Interestingly, BZLF1-specific T cells were not lost in all progressors to NHL, suggesting a different function of these cells in the surveillance of EBV-infected B cells.

[MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Epstein-Barr Virus Nuclear Antigens / immunology. Immunologic Memory / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / immunology

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Genetic Alliance. consumer health - HIV.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16014568.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Oral manifestations of HIV/AIDS in clients attending TASO clinics in Uganda.

A total of 514 subjects aged 18 to 58 years (mean 42 years) were randomly recruited from five The AIDS Support Organization (TASO) clinics in Uganda.

Non-Hodgkin's lymphoma, atypical ulcers, necrotizing periodontitis, and hairy leucoplakia were least frequently observed in the subjects.

[MeSH-minor] AIDS-Related Opportunistic Infections / epidemiology. Adolescent. Adult. Burning Mouth Syndrome / epidemiology. Candidiasis, Oral / epidemiology. Cheilitis / epidemiology. Cross-Sectional Studies. Female. Gingivitis, Necrotizing Ulcerative / epidemiology. Humans. Leukoplakia, Hairy / epidemiology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Male. Middle Aged. Oral Ulcer / epidemiology. Periodontitis / epidemiology. Prevalence. Sex Factors. Uganda / epidemiology. Xerostomia / epidemiology

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - Mouth Disorders.

HIV InSite. treatment guidelines - Serious Bacterial (Pediatric) .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Oral Dis. 2002;8 Suppl 2:34-9 [12164657.001]

[Cites] Rev Panam Salud Publica. 2003 Aug;14(2):112-8 [14577934.001]

[Cites] West Afr J Med. 2002 Jan-Mar;21(1):9-11 [12081356.001]

[Cites] AIDS Patient Care STDS. 2002 Oct;16(10):479-86 [12437859.001]

[Cites] Oral Dis. 2002;8 Suppl 2:110-4 [12164643.001]

[Cites] Oral Dis. 2006 Nov;12(6):537-42 [17054765.001]

[Cites] Cent Afr J Med. 1998 Feb;44(2):31-4 [9675968.001]

[Cites] Medicine (Baltimore). 2003 Jan;82(1):39-50 [12544709.001]

[Cites] J Oral Pathol Med. 1990 May;19(5):232-4 [2359042.001]

[Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Jun;87(6):708-13 [10397663.001]

[Cites] Adv Dent Res. 2006 Apr 01;19(1):106-17 [16672560.001]

[Cites] Trop Med Int Health. 1999 May;4(5):349-54 [10402970.001]

[Cites] Oral Dis. 2002;8 Suppl 2:136-43 [12164647.001]

[Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Mar;89(3):299-304 [10710453.001]

[Cites] Qual Life Res. 2002 Feb;11(1):57-70 [12003056.001]

[Cites] Oral Dis. 2002;8 Suppl 2:80-7 [12164666.001]

[Cites] J Oral Pathol Med. 1999 Apr;28(4):173-7 [10235371.001]

[Cites] Med Oral Patol Oral Cir Bucal. 2004;9 Suppl:153-7; 148-53 [15580133.001]

[Cites] AIDS Patient Care STDS. 2000 Dec;14(12):627-35 [11119429.001]

[Cites] J Oral Pathol Med. 1998 Apr;27(4):176-9 [9563573.001]

(PMID = 17476537.001).

[ISSN] 1432-6981

[Journal-full-title] Clinical oral investigations

[ISO-abbreviation] Clin Oral Investig

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Circulating serum free light chains as predictive markers of AIDS-related lymphoma.

PURPOSE HIV-infected persons have an elevated risk of developing non-Hodgkin's lymphoma (NHL); this risk remains increased in the era of effective HIV therapy.

We evaluated serum immunoglobulin (Ig) proteins as predictors of NHL risk among HIV-infected individuals.

PATIENTS AND METHODS By using three cohorts of HIV-infected persons (from 1982 to 2005), we identified 66 individuals who developed NHL and 225 matched (by cohort, sex, ethnicity, age, and CD4 count), HIV-infected, lymphoma-free controls who had available stored prediagnostic blood samples.

Results The kappa and lambda FLCs were both significantly higher in patients (eg, in 2- to 5-year window: median kappa, 4.24 v 3.43 mg/dL; median lambda, 4.04 v 3.09 mg/dL) and strongly predicted NHL in a dose-response manner up to 2 to 5 years before diagnosis/selection (eg, NHL risk 3.76-fold higher with kappa concentration at least 2.00 times the upper limit of normal, and 8.13-fold higher with lambda concentration at least 2.00 times the upper limit of normal compared with normal levels).

M proteins were detected in only two patients with NHL (3%) and in nine controls (4%), and they were not significantly associated with NHL risk.

CONCLUSION Elevated FLCs may represent sensitive markers of polyclonal B-cell activation and dysfunction and could be useful for identifying HIV-infected persons at increased NHL risk.

[MeSH-major] Biomarkers, Tumor / blood. Immunoglobulin kappa-Chains / blood. Immunoglobulin lambda-Chains / blood. Lymphoma, AIDS-Related / immunology

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Rev Immunol. 2009 Apr;9(4):235-45 [19319142.001]

[Cites] Ann Rheum Dis. 2009 Jan;68(1):89-93 [18375535.001]

[Cites] Blood. 2009 May 28;113(22):5412-7 [19179464.001]

[Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):78-84 [20418723.001]

[Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]

[Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]

[Cites] Blood. 2001 May 1;97(9):2900-2 [11313287.001]

[Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]

[Cites] Clin Chem. 2002 Sep;48(9):1437-44 [12194920.001]

[Cites] Blood. 2003 Nov 15;102(10):3759-64 [12881316.001]

[Cites] Curr HIV Res. 2004 Jan;2(1):11-21 [15053337.001]

[Cites] AIDS Read. 2004 Jul;14(7):372-4, 377-9 [15282866.001]

[Cites] N Engl J Med. 2004 Oct 7;351(15):1548-63 [15470219.001]

[Cites] N Engl J Med. 1983 Aug 25;309(8):453-8 [6224088.001]

[Cites] JAMA. 1987 Jan 16;257(3):331-4 [3491911.001]

[Cites] Clin Chem. 1987 Sep;33(9):1697-8 [3621592.001]

[Cites] Clin Chem. 1989 Feb;35(2):338-9 [2914402.001]

[Cites] N Engl J Med. 1989 Oct 26;321(17):1141-8 [2477702.001]

[Cites] Br J Haematol. 1993 May;84(1):151-5 [8101720.001]

[Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]

[Cites] Leukemia. 1997 Dec;11(12):2150-6 [9447834.001]

[Cites] Int J Cancer. 2005 Jun 10;115(2):296-300 [15688390.001]

[Cites] Blood. 2005 Aug 1;106(3):812-7 [15855274.001]

[Cites] Haemophilia. 2005 Sep;11(5):516-28 [16128897.001]

[Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]

[Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]

[Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]

[Cites] Curr Opin Oncol. 2006 Sep;18(5):444-8 [16894291.001]

[Cites] Clin Infect Dis. 2006 Nov 1;43(9):1198-205 [17029142.001]

[Cites] Ann Rheum Dis. 2007 Jan;66(1):23-7 [16569685.001]

[Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]

[Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]

[Cites] JAMA. 2008 Aug 6;300(5):555-70 [18677028.001]

[Cites] N Engl J Med. 2009 Apr 30;360(18):1815-26 [19339714.001]

(PMID = 20048176.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Grant] United States / Intramural NIH HHS / / Z01 CP010150-08; United States / NCI NIH HHS / CA / P01 CA062242; United States / NCI NIH HHS / CA / CA 107476; United States / NCI NIH HHS / CA / R01 CA107476; United States / NCI NIH HHS / CA / CA 62242

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains

[Other-IDs] NLM/ PMC2834393

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].

[Transliterated title] Lymphomes non hodgkiniens et hodgkiniens et infection VIH: fréquence, pronostic et reconstitution immune sous trithérapie antirétrovirale; CHU de Clermont-Ferrand, 1991-2003.

OBJECTIVES: The authors had for aim to identify cases of non Hodgkin's (NHL) and Hodgkin's (HL) lymphomas in HIV1-infected patients to assess 1) their incidence, before and after 1996, 2) the clinical features and outcome under treatment together with the survival rate of the patients, 3) the immune reconstitution of lymphoma-free patients under HAART.

PATIENTS AND METHODS: A retrospective study was made of HIV1-infected patients managed at the Clermont-Ferrand University Hospital from 1991 to 2003 for the diagnosis and treatment of HIV1-related lymphomas.

RESULTS: Forty-one patients were included: 35 NHL and 6 HL giving a cumulative incidence rate estimate from 2.4% between 1991 and 1996 to 3.4% between 1997 and 2003 while other opportunistic diseases were decreasing.

A high proportion of aggressive and disseminated disease was observed among NHL cases.

Complete remission was achieved in 17 (49%) and 5 (83%) NHL and HL cases respectively.

The mean survival was 109+/-54 months and was correlated with CD4 cell count at lymphoma diagnosis (univariate analysis).

Immune restoration in lymphoma-free patients under HAART is poor.

[MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. HIV-1. Hodgkin Disease / epidemiology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology

[MeSH-minor] AIDS-Related Opportunistic Infections / epidemiology. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Cohort Studies. Female. France / epidemiology. Hospitals, University / statistics & numerical data. Humans. Incidence. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

MedlinePlus Health Information. consumer health - Hodgkin Disease.

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16503104.001).

[ISSN] 0399-077X

[Journal-full-title] Médecine et maladies infectieuses

[ISO-abbreviation] Med Mal Infect

[Language] fre

[Publication-type] English Abstract; Journal Article

[Publication-country] France

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Attenuation of the epidemic increase in non-Hodgkin's lymphomas in Spain.

BACKGROUND: Attenuation of the epidemic increase in non-Hodgkin's lymphoma (NHL) incidence has recently been reported in the USA and Nordic European countries.

After two decades of steadily increasing NHL, this study sought to ascertain whether a similar stabilisation might have taken place in Spain in recent years.

PATIENTS AND METHODS: NHL cases were drawn from 13 population-based Spanish cancer registries with a record of at least 10 years of uninterrupted registration during the period 1975-2004.

RESULTS: A total of 21 335 NHL cases (11 531 male and 9804 female) were identified.

CONCLUSIONS: In Spain, NHL incidence levelled off in 1996 after a sharp increase during the 1970s and 1980s.

This stabilisation is, partially at least, linked to the decrease in incidence of AIDS-related lymphomas among young adults.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20427366.001).

[ISSN] 1569-8041

[Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology

[ISO-abbreviation] Ann. Oncol.

[Language] ENG

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Investigator] Dorronsorro M; Giraldo P; Díaz García JM; Gutiérrez G; Gutiérrez L; Pérez de Rada E

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma.

CXCL13/CXCR5 are expressed, and may play a role, in some non-AIDS-associated B cell tumors.

Objective. To determine if CXCL13/CXCR5 are associated with AIDS-related non-Hodgkin's lymphoma (AIDS-NHL).

Methods. Serum CXCL13 levels were measured by ELISA in 46 subjects who developed AIDS-NHL in the Multicenter AIDS Cohort Study and in controls.

The expression or function of CXCL13 and CXCR5 was examined on primary AIDS-NHL specimens or AIDS-NHL cell lines.

Results. Serum CXCL13 levels were significantly elevated in the AIDS-NHL group compared to controls.

All primary AIDS-NHL specimens showed CXCR5 expression and most also showed CXCL13 expression.

AIDS-NHL cell lines expressed CXCR5 and showed chemotaxis towards CXCL13.

Conclusions. CXCL13/CXCR5 are expressed in AIDS-NHL and could potentially be involved in its biology.

CXCL13 may have potential as a biomarker for AIDS-NHL.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Pathol. 2008 Aug;215(4):431-44 [18561120.001]

[Cites] J Neuroimmunol. 2008 Jul 31;198(1-2):106-12 [18539341.001]

[Cites] Blood. 2009 May 7;113(19):4604-13 [19228923.001]

[Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]

[Cites] J Clin Oncol. 1993 Jun;11(6):1099-107 [8099121.001]

[Cites] Blood. 1994 Feb 15;83(4):1067-78 [8111047.001]

[Cites] Cell. 1996 Dec 13;87(6):1037-47 [8978608.001]

[Cites] Blood. 1997 Jul 15;90(2):520-5 [9226150.001]

[Cites] J Exp Med. 1998 Feb 16;187(4):655-60 [9463416.001]

[Cites] Nature. 1998 Feb 19;391(6669):799-803 [9486651.001]

[Cites] Oncology (Williston Park). 2001 Apr;15(4):439-48; discussion 448-9 [11346932.001]

[Cites] Curr Opin Oncol. 2002 Sep;14(5):528-32 [12192272.001]

[Cites] Ophthalmology. 2003 Feb;110(2):421-6 [12578791.001]

[Cites] Tumour Biol. 2003 Mar-Apr;24(2):82-93 [12853703.001]

[Cites] Breast Dis. 2004;20:137-43 [15687714.001]

[Cites] J Natl Cancer Inst. 1991 May 15;83(10):695-701 [2023270.001]

[Cites] Blood. 1995 Jun 15;85(12):3423-30 [7780129.001]

[Cites] Biochem Biophys Res Commun. 1997 Jun 27;235(3):576-81 [9207199.001]

[Cites] Blood. 1999 Mar 15;93(6):1838-42 [10068655.001]

[Cites] Blood Rev. 1999 Sep;13(3):147-50 [10527266.001]

[Cites] Immunology. 2000 Feb;99(2):266-71 [10692046.001]

[Cites] Immunity. 2000 Feb;12(2):121-7 [10714678.001]

[Cites] Immunol Rev. 2000 Aug;176:181-93 [11043777.001]

[Cites] Biochem Biophys Res Commun. 2001 Mar 30;282(2):369-75 [11401467.001]

[Cites] Eur J Cancer. 2001 Jul;37(10):1270-5 [11423258.001]

[Cites] Cancer Res. 2001 Jul 1;61(13):5028-37 [11431337.001]

[Cites] Blood. 2002 Jan 1;99(1):207-12 [11756173.001]

[Cites] Nature. 2002 Mar 7;416(6876):94-9 [11882900.001]

[Cites] Cancer Res. 2002 Jun 1;62(11):3106-12 [12036921.001]

[Cites] J Leukoc Biol. 2002 Jul;72(1):1-8 [12101256.001]

[Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]

[Cites] J Virol. 2003 Feb;77(3):2271-5 [12525664.001]

[Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86 [12626353.001]

[Cites] Blood. 2004 Jul 15;104(2):502-8 [15001469.001]

[Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]

[Cites] Int J Dev Biol. 2004;48(5-6):489-96 [15349823.001]

[Cites] AIDS. 2005 Oct 14;19(15):1711-2 [16184051.001]

[Cites] J Interferon Cytokine Res. 2005 Nov;25(11):702-6 [16318584.001]

[Cites] Acta Neuropathol. 2007 Sep;114(3):271-6 [17641901.001]

[Cites] Blood. 2007 Nov 1;110(9):3316-25 [17652619.001]

[Cites] Immunity. 2007 Aug;27(2):190-202 [17723214.001]

[Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]

[Cites] Blood. 2008 Mar 15;111(6):3200-10 [18184868.001]

[Cites] Blood. 2008 Dec 1;112(12):4401-10 [18780835.001]

(PMID = 21490903.001).

[ISSN] 2090-1259

[Journal-full-title] AIDS research and treatment

[ISO-abbreviation] AIDS Res Treat

[Language] ENG

[Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NCI NIH HHS / CA / R01 CA073475; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NCI NIH HHS / CA / R01 CA057152; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIAID NIH HHS / AI / U01 AI035039

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC3065842

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Changes in causes of death and associated conditions among persons with HIV/AIDS after the introduction of highly active antiretroviral therapy in Taiwan.

To assess the pattern of change in the causes of death among HIV/AIDS patients in Taiwan after the introduction of highly active antiretroviral therapy (HAART), national HIV/AIDS registry data were linked with cause of death and health insurance claims data from 1994 to 2002 for analysis.

Although HIV/AIDS remained the leading underlying cause of death among HIV/AIDS patients during the study period (552/752 = 73.4%), an increased proportion of deaths was due to non-HIV/AIDS causes (other infectious diseases, cancers, liver diseases, etc.) after the introduction of HAART in 1997.

Most AIDS-related conditions associated with death (cryptococcosis, cachexia/wasting, dementia/encephalopathy, etc.) decreased in frequency from 1998-2000 to 2001-2002.

Nonetheless, some AIDS-related conditions associated with death remained stable or increased in frequency, such as candidiasis, tuberculosis, and non-Hodgkin's lymphoma.

More effort is required to address the mental health of HIV/AIDS patients as a part of therapy.

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

HIV InSite. treatment guidelines - Non-ARV Adverse Events .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16877243.001).

[ISSN] 0929-6646

[Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi

[ISO-abbreviation] J. Formos. Med. Assoc.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Singapore

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS and associated malignancies.

AIDS associated malignancies (ARL) is a major complication associated with AIDS patients upon immunosuppression.

Malignancies that were found to have high incidence in HIV-infected individuals are Kaposi's sarcoma (KS), Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).

The incidence of NHL has increased nearly 200 fold in HIV-positive patients, and accounts for a greater percentage of AIDS defining illness in the US and Europe since the advent of HAART therapy.

These AIDS related lymphomas are distinct from their counterparts seen in HIV-1 seronegative patients.

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16354573.001).

[ISSN] 1001-0602

[Journal-full-title] Cell research

[ISO-abbreviation] Cell Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA082274; United States / NCI NIH HHS / CA / CA76958; United States / NICHD NIH HHS / HD / HD39620; United States / NCRR NIH HHS / RR / RR15635

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review

[Publication-country] China

[Number-of-references] 60

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS and non AIDS-related malignant lymphoma in Tanzania.

BACKGROUND: Malignant lymphoma (ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as AIDS-defining tumors.

In Africa the frequency of AIDS-related lymphoma (ARL) is rare and the findings are controversial.

Both retrospective and prospective lymphoma cases were classified according to the revised European-American (REAL) classification.

OBJECTIVES: To determine the frequency and type of AIDS and non-AIDS related malignant lymphoma in Tanzania and a possible co-association with KSHV/HHV-8 and EBV.

The tumors were classified as Burkitt's (6), diffuse large cell (10), precursor-B lymphoblastic (1) and Hodgkin's disease (5) from HIV positive and negative patients.

Ten (40%) high grade ML and three Hodgkin's lymphoma from HIV patients had HHV-8 DNA.

These findings were not related to age, sex or type of lymphoma.

There was no association of HHV-8 with the lymphoma cells.

[MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma, AIDS-Related / epidemiology

[MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Developing Countries. Female. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Polymerase Chain Reaction. Registries. Retrospective Studies. Risk Assessment. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / virology. Survival Analysis. Tanzania / epidemiology. Young Adult

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Natl Cancer Inst Monogr. 1998;(23):79-88 [9709308.001]

[Cites] Br J Cancer. 1997;75(11):1704-7 [9184191.001]

[Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]

[Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]

[Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]

[Cites] Scand J Infect Dis. 1994;26(6):749-52 [7747100.001]

[Cites] Int J Cancer. 1995 May 16;61(4):574-9 [7759163.001]

[Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]

[Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]

[Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):295-305 [7552491.001]

[Cites] AIDS. 2002 Mar 8;16(4):597-603 [11873003.001]

[Cites] J Med Virol. 2002 Oct;68(2):264-7 [12210417.001]

[Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]

[Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):375-405 [15129649.001]

[Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]

[Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]

[Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]

[Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]

[Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]

[Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]

[Cites] N Engl J Med. 1996 Jan 25;334(4):272-3 [8532016.001]

[Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]

[Cites] Br J Haematol. 1995 Dec;91(4):918-20 [8547139.001]

[Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]

[Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]

[Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]

[Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]

[Cites] J Mol Med (Berl). 1995 Dec;73(12):603-9 [8825757.001]

[Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]

[Cites] J Virol. 1997 Mar;71(3):2505-11 [9032391.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

(PMID = 16916294.001).

[ISSN] 1729-0503

[Journal-full-title] African health sciences

[ISO-abbreviation] Afr Health Sci

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Uganda

[Other-IDs] NLM/ PMC1831982

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

PURPOSE OF REVIEW: India has the second largest number of HIV/AIDS patients in the world; however, studies done in the area of HIV-related malignancies are few.

With the availability of highly active antiretroviral therapy and treatment and prevention of opportunistic infections, an increase in life expectancy of HIV-infected individuals and an increase in HIV-related malignancies is expected.

The purpose of this review is to put forth the Indian scenario of HIV-related malignancies.

RECENT FINDINGS: About 2.5 million Indians have HIV/AIDS.

Non-Hodgkin's lymphoma and cervical cancer were found to occur in a higher proportion among the HIV-infected individuals in India as compared with non-HIV-infected individuals.

The incidence of AIDS-related primary central nervous system lymphoma is low in India.

Amongst the non-AIDS defining cancers anal cancer, testicular cancer, Hodgkin's disease, colon cancer and certain head and neck cancer sites in men and vaginal cancers among women were found to occur more frequently.

As India is a large country and geographically and culturally diverse, large-scale studies need to be done linking the regional cancer centres with the AIDS centres across the country to evaluate the exact burden of HIV-related malignancies.

[MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / etiology. Neoplasms / etiology

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19106653.001).

[ISSN] 1531-703X

[Journal-full-title] Current opinion in oncology

[ISO-abbreviation] Curr Opin Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 37

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related malignancies: state of the art and therapeutic challenges.

Despite the impact of combination antiretroviral therapy (cART) on HIV-related mortality, malignancy remains an important cause of death in the current era.

Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.

Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.

Special considerations of these AIDS-related and non-AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review.

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18591544.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 99

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Update in HIV lymphoma.

Lymphoma is the most common HIV-associated malignancy in these countries.

RECENT FINDINGS: Investigators continue to demonstrate that HIV-associated non-Hodgkin's lymphoma remains a significant problem, even in the era of highly active antiretroviral therapy.

The majority of work has been in diffuse large B-cell lymphoma, with infusional therapy remaining promising, and rituximab an area of investigation.

Biological insights have been gained into the spectrum of HIV-associated non-Hodgkin's lymphoma and Hodgkin's disease, and include further work on virological co-infections.

SUMMARY: The outcome for individuals infected with HIV and developing non-Hodgkin's lymphoma and Hodgkin's disease continues to improve as insights into the pathophysiology and treatment advance.

[MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16894292.001).

[ISSN] 1040-8746

[Journal-full-title] Current opinion in oncology

[ISO-abbreviation] Curr Opin Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-Retroviral Agents

[Number-of-references] 45

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Several studies have reported the feasibility, safety, and efficacy of autologous HSCT as rescue or consolidation treatment for non-Hodgkin's and Hodgkin's lymphoma in HIV-infected patients.

[MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, AIDS-Related / therapy

[MeSH-minor] Hodgkin Disease / complications. Hodgkin Disease / therapy. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / therapy. Transplantation Conditioning / methods. Treatment Outcome

Genetic Alliance. consumer health - Transplantation.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Exp Hematol. 2005 Apr;33(4):487-94 [15781340.001]

[Cites] J Infect Dis. 2000 Jan;181(1):148-57 [10608761.001]

[Cites] Blood. 1996 Nov 1;88(9):3329-35 [8896397.001]

[Cites] Transplantation. 2006 Jun 27;81(12):1658-61 [16794531.001]

[Cites] Cancer. 1994 May 1;73(9):2400-7 [8168044.001]

[Cites] Med Clin (Barc). 2008 Mar 8;130(8):300-11 [18358123.001]

[Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]

[Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]

[Cites] Blood. 2009 Aug 13;114(7):1306-13 [19451551.001]

[Cites] Exp Hematol. 2002 Mar;30(3):279-84 [11882366.001]

[Cites] Blood. 2009 Jun 4;113(23):6011-4 [19307667.001]

[Cites] Biol Blood Marrow Transplant. 2009 Jul;15(7):864-71 [19539219.001]

[Cites] Bone Marrow Transplant. 2010 Mar;45(3):584-6 [19617906.001]

[Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]

[Cites] Clin Infect Dis. 2000 Mar;30(3):504-10 [10722435.001]

[Cites] AIDS. 2002 Apr 12;16(6):865-76 [11919488.001]

[Cites] J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):422-8 [18434957.001]

[Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]

[Cites] Leuk Lymphoma. 2008 Jun;49(6):1155-60 [18452074.001]

[Cites] Curr Opin Oncol. 2007 Sep;19(5):446-51 [17762569.001]

[Cites] AIDS Read. 2004 Jul;14(7):372-4, 377-9 [15282866.001]

[Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]

[Cites] J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):289-90 [10969356.001]

[Cites] AIDS. 2002 Sep 27;16(14):1973-6 [12351963.001]

[Cites] Biol Blood Marrow Transplant. 2011 Apr;17(4):586-7 [19892025.001]

[Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]

[Cites] Haematologica. 2004 Sep;89(9):1100-8 [15377471.001]

[Cites] Biol Blood Marrow Transplant. 2008 May;14(5):601-2 [18410904.001]

[Cites] Bone Marrow Transplant. 2005 Aug;36(3):261-2 [15908966.001]

[Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):27-34 [19339937.001]

[Cites] J Clin Oncol. 2009 May 1;27(13):2192-8 [19332732.001]

[Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]

[Cites] Blood. 2002 Jan 15;99(2):698-701 [11781257.001]

[Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):167-73 [17117144.001]

[Cites] AIDS Res Hum Retroviruses. 2000 Oct 10;16(15):1471-9 [11054260.001]

[Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):11-5 [19339935.001]

[Cites] Blood. 2008 Oct 15;112(8):3484-7 [18698002.001]

[Cites] J Virol. 1999 Nov;73(11):9089-97 [10516015.001]

[Cites] Haematologica. 2007 Apr;92(4):e56-8 [17562594.001]

[Cites] Blood. 1998 Feb 1;91(3):907-15 [9446651.001]

[Cites] Ann Intern Med. 1988 May;108(5):744-53 [3358573.001]

[Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]

[Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]

[Cites] AIDS. 2009 Jun 1;23(9):1069-76 [19417577.001]

(PMID = 20549392.001).

[ISSN] 1548-3576

[Journal-full-title] Current HIV/AIDS reports

[ISO-abbreviation] Curr HIV/AIDS Rep

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.

Rituximab (chimeric anti-CD20 monoclonal antibodies) is currently being used in the treatment of B non-Hodgkin's lymphoma (NHL).

We have recently reported that rituximab triggers and modifies various intracellular signaling pathways in NHL B-cell lines, resulting in reverting the chemoresistant phenotype to a sensitive phenotype.

This study investigated whether rituximab also modifies intracellular signaling pathways resulting in the sensitization of NHL cells to Fas-induced apoptosis.

Treatment of the Fas-resistant NHL cell lines (2F7, Ramos and Raji) with rituximab sensitized the cells to CH-11 (FasL agonist mAb)-induced apoptosis and synergy was achieved.

These findings provide a novel mechanism of rituximab-mediated activity by sensitizing NHL cells to Fas-induced apoptosis.

[MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD95 / immunology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Lymphoma, B-Cell / pathology

[MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / immunology. Burkitt Lymphoma / pathology. Cell Line, Tumor. Cell Survival / drug effects. Enzyme Inhibitors / pharmacology. Gene Expression Regulation, Neoplastic. Humans. Imidazoles / pharmacology. Lymphoma, AIDS-Related. NF-kappa B / pharmacology. Pyridines / pharmacology. Rituximab. Transcription, Genetic / drug effects. p38 Mitogen-Activated Protein Kinases / metabolism

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. RITUXIMAB .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16103877.001).

[ISSN] 0950-9232

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] eng

[Grant] United States / NIAID NIH HHS / AI / AI28697; United States / FIC NIH HHS / TW / D43 TW00013-14

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Imidazoles; 0 / NF-kappa B; 0 / Pyridines; 0 / SB 203580; 4F4X42SYQ6 / Rituximab; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.

Central nervous system (CNS) lymphoma should always be considered because it is an important cause of morbidity and mortality.

RESULTS: FCI and cytology gave concordant results for 48 of the 56 CSF samples studied: 37 were negative for malignancy and 11 had evidence of CNS lymphoma.

This advantage suggests that, in case of negative flow cytometry results, disorders other than non-Hodgkin's lymphoma should be strongly considered.

[MeSH-major] Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis

[MeSH-minor] Adult. Burkitt Lymphoma / cerebrospinal fluid. Burkitt Lymphoma / diagnosis. Diagnosis, Differential. Female. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15670248.001).

[ISSN] 1464-2662

[Journal-full-title] HIV medicine

[ISO-abbreviation] HIV Med.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.

PURPOSE: Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype.

PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006.

RESULTS: Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001).

Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).

CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk.

Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.

Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]

[Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]

[Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]

[Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]

[Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]

[Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]

[Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]

[Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]

[Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]

[Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]

[Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]

[Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]

[Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]

[Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]

[Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]

[Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]

[Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]

[Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]

[Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]

[Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]

[Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]

[Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]

[Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]

[Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]

[Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]

[Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]

[Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]

[Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]

[Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]

[Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]

[Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]

[Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]

[Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]

[Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]

[Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]

[Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]

[Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]

[Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]

[Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]

[Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]

[Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]

[Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]

[Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]

[Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]

[Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]

[Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]

[Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]

[Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]

[Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]

[Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]

[Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]

[Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]

(PMID = 20940199.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] ENG

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

[Other-IDs] NLM/ PMC3020697

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy.

BACKGROUND AND OBJECTIVES: Lymphoma is the fourth most frequent malignancy diagnosed during pregnancy, occurring in approximately 1 over 6000 deliveries.

DESIGN AND METHODS: Its occurrence may increase due to the current trend to postpone pregnancy until later in life and the evidence suggested high incidence of AIDS-related non-Hodgkin's lymphoma in developing countries.

The relatively rare occurrence of pregnancy-associated lymphoma precludes the conduction of large, prospective studies to examine diagnostic, management and outcome issues.

In the vast majority of cases, when lymphoma is diagnosed during the first trimester, treatment with a standard chemotherapy regimen, following pregnancy termination should be recommended.

In the rare patients at low risk, such as those with stage 1 Hodgkin's lymphoma or indolent non-Hodgkins lymphoma, therapy can be delayed until the end of the first trimester and of embryogenesis while keeping the patients under close observation.

INTERPRETATION AND CONCLUSIONS: When lymphoma is diagnosed during the second and third trimesters, evidence exists suggesting that full-dose chemotherapy can be administered safely without apparent increased risk of severe adverse fetal outcome.

[MeSH-major] Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Pregnancy Complications, Neoplastic / therapy

Genetic Alliance. consumer health - Pregnancy.

MedlinePlus Health Information. consumer health - Hodgkin Disease.

MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17666365.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Italy

[Number-of-references] 67

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cancer incidence in AIDS patients in Catalonia, Spain.

HIV infected people and AIDS patients develop cancer more frequently than the general population.

The objective of this study was to evaluate the risk of developing cancer among 15 to 69 year old AIDS patients from two geographic areas: Tarragona and Girona provinces, in north-eastern Spain.

We have studied invasive and in situ cancers (for all sites) among 1659 AIDS patients from +/-5 years around the date of their AIDS diagnosis by matching the population-based Cancer Registries with the AIDS Registry covering these populations.

Compared with the general population, incidence of cancer among AIDS patients (invasive and in situ) increased 22.9 fold in men (n=142) and 21.0 fold in women (n=45).

High statistically significant SIRs were found for Kaposi's sarcoma (KS) (male, 486.4; female, 1030.0), non-Hodgkin's lymphoma (NHL) (male, 126.1; female, 192.8) and invasive cervical cancer (41.8).

High risks were also found for Hodgkin's lymphoma (31.1), liver cancer (29.4) and lung cancer (9.4) in men, and in situ cervical cancer (24.4) in women.

For all non-AIDS defining malignant neoplasms as a group SIRs were 3.4 in men and 2.5 in women.

Among men, homo/bisexuality was strongly related to risk of KS and NHL.

The rates of cervical cancer, Hodgkin's lymphoma, liver cancer and lung cancer were among the highest ever reported linked to HIV infection.

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17349785.001).

[ISSN] 0959-8049

[Journal-full-title] European journal of cancer (Oxford, England : 1990)

[ISO-abbreviation] Eur. J. Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.

The clinical application of rituximab (chimeric mouse anti-human CD20 mAb, Rituxan, IDEC-C2B8), alone and/or combined with chemotherapy, has significantly ameliorated the treatment outcome of patients with relapsed and refractory low-grade or follicular non-Hodgkin's lymphoma (NHL).

Monomeric rituximab chemosensitizes drug-resistant NHL cells via selective downregulation of antiapoptotic factors through the type II mitochondrial apoptotic pathway.

ARL (acquired immunodeficiency syndrome (AIDS)-related lymphoma) and non-ARL cell lines have been examined as in vitro model systems.

Rituximab upregulates Raf-1 kinase inhibitor protein (RKIP) expression in non-ARL cells.

Downmodulation of the ERK1/2 and NF-kappa B pathways inhibits the transcriptional activity of AP-1 and NF-kappa B transcription factors, respectively, both of which lead to the downregulation of Bcl-(xL) (Bcl-2 related gene (long alternatively spliced variant of Bcl-x gene)) transcription and expression and sensitization to drug-induced apoptosis.

Rituximab-resistant B-NHL clones were generated to investigate the acquired resistance to rituximab-mediated signaling, and chemosensitization.

Studies presented herein also reveal several intracellular targets modified by rituximab, which can be exploited for therapeutic and prognostic purposes in the treatment of patients with rituximab- and drug-refractory NHL.

[MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Signal Transduction / drug effects

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. RITUXIMAB .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15789036.001).

[ISSN] 0950-9232

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Recombinant Fusion Proteins; 4F4X42SYQ6 / Rituximab

[Number-of-references] 250

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center.

AIMS: To analyze clinical features and survival in HIV-associated non-Hodgkin lymphoma (NHL) cases registered at Dr BRA Institute Rotary Cancer Hospital of AIIMS, New Delhi.

MATERIALS AND METHODS: We have retrospectively reviewed records of NHL patients registered, from January 2003 to July 2007 to analyze HIV-associated NHL.

RESULTS: Seven cases of HIV-associated NHL cases were identified.

Three cases had nodal lymphoma and four had extra nodal lymphoma.

No primary CNS (PCNSL) lymphoma was seen.

Six cases had high-grade NHL.

HIV infection was diagnosed as part of NHL work-up in five patients.

CONCLUSIONS: These NHL are of higher grade and advanced stage.

[MeSH-major] HIV Infections / complications. HIV Infections / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / virology

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Indian J Cancer. 2010 Jan-Mar;47(1):6-7 [20071782.001]

(PMID = 20071788.001).

[ISSN] 1998-4774

[Journal-full-title] Indian journal of cancer

[ISO-abbreviation] Indian J Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature.

BACKGROUND: The risk of developing lymphoma is greatly increased in HIV infection.

HIV-related neoplastic processes that affect the musculoskeletal system include Kaposi's sarcoma and non-Hodgkin's lymphoma, the latter being mainly localized at lower extremities, spine and skull.

A final diagnosis of diffuse large B-cell lymphoma was made.

CONCLUSION: In this report, we present a case of diffuse large B-cell lymphoma localized in the soft tissue of the shoulder in a HIV infected patient.

[MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Pregnancy Complications, Neoplastic / pathology. Pregnancy Outcome. Soft Tissue Neoplasms / pathology

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Med Interne (Paris). 2003 Dec;154(8):523-8 [15037828.001]

[Cites] J Am Acad Dermatol. 2003 May;48(5 Suppl):S82-5 [12734486.001]

[Cites] Radiology. 1980 Feb;134(2):521-3 [7352243.001]

[Cites] Am J Surg Pathol. 1987 May;11(5):359-66 [3578646.001]

[Cites] Br J Radiol. 1989 Jan;62(733):81 [2914198.001]

[Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):455-9 [7790558.001]

[Cites] Bol Asoc Med P R. 1995 Oct-Dec;87(10-12):158-61 [8924158.001]

[Cites] Crit Rev Diagn Imaging. 1996 Sep;37(4):305-47 [8894398.001]

[Cites] Clin Radiol. 1997 Mar;52(3):203-12 [9091255.001]

[Cites] Radiol Clin North Am. 1997 Sep;35(5):1167-89 [9298091.001]

[Cites] Am J Orthop (Belle Mead NJ). 1998 Feb;27(2):128-34 [9506198.001]

[Cites] Semin Ultrasound CT MR. 1998 Apr;19(2):200-8 [9567324.001]

[Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]

[Cites] Am J Surg Pathol. 1999 Jan;23(1):88-96 [9888708.001]

[Cites] Clin Orthop Relat Res. 1999 Mar;(360):221-30 [10101328.001]

[Cites] Leuk Lymphoma. 2006 Feb;47(2):329-32 [16321866.001]

[Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]

[Cites] Leukemia. 2007 Feb;21(2):207-14 [17170731.001]

[Cites] AJR Am J Roentgenol. 2007 Jun;188(6):1443-5 [17515361.001]

[Cites] J Am Acad Orthop Surg. 2002 Sep-Oct;10(5):312-20 [12374482.001]

[Cites] Rev Chir Orthop Reparatrice Appar Mot. 2002 Sep;88(5):518-21 [12399719.001]

[Cites] Leuk Lymphoma. 2002 Dec;43(12):2405-7 [12613532.001]

[Cites] Skeletal Radiol. 2004 Jun;33(6):311-20 [15127244.001]

(PMID = 18939988.001).

[ISSN] 1477-7819

[Journal-full-title] World journal of surgical oncology

[ISO-abbreviation] World J Surg Oncol

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] England

[Number-of-references] 24

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Of all patients, only two were females including one who had non-Hodgkin's lymphoma and was HIV negative.

[MeSH-major] AIDS-Related Opportunistic Infections / immunology. AIDS-Related Opportunistic Infections / mortality. JC Virus / immunology. Leukoencephalopathy, Progressive Multifocal / immunology. Leukoencephalopathy, Progressive Multifocal / mortality

[MeSH-minor] Adult. Antibodies, Viral / blood. Antiretroviral Therapy, Highly Active. Female. Follow-Up Studies. Humans. Lymphoma, Non-Hodgkin / mortality. Magnetic Resonance Imaging. Male. Middle Aged. Time Factors. Treatment Outcome

Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.

MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neurovirol. 2003 Jun;9(3):411-9 [12775425.001]

[Cites] J Neurovirol. 2003;9 Suppl 1:88-92 [12709878.001]

[Cites] N Engl J Med. 2004 Apr 29;350(18):1882-93 [15115835.001]

[Cites] Brain. 2004 Sep;127(Pt 9):1970-8 [15215217.001]

[Cites] Stroke. 1989 Jun;20(6):828 [2728057.001]

[Cites] J Neurovirol. 1998 Feb;4(1):59-68 [9531012.001]

[Cites] Science. 2004 Nov 19;306(5700):1380-3 [15550673.001]

[Cites] N Engl J Med. 2005 Jul 28;353(4):414-6 [15947082.001]

[Cites] J NeuroAIDS. 1996;1(4):79-88 [16873181.001]

[Cites] Ann Neurol. 2006 Aug;60(2):162-73 [16862584.001]

[Cites] J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):26-31 [18667930.001]

[Cites] AIDS. 2008 Sep 12;22(14):1759-67 [18753934.001]

[Cites] J Infect Dis. 2009 Jan 1;199(1):77-83 [19007313.001]

[Cites] Virology. 2009 Jan 20;383(2):173-7 [19062062.001]

[Cites] J Neurovirol. 2001 Aug;7(4):386-90 [11517422.001]

[Cites] Clin Infect Dis. 2003 Apr 15;36(8):1047-52 [12684918.001]

[Cites] J Neurovirol. 2003;9 Suppl 1:47-53 [12709872.001]

[Cites] AIDS. 2003 Jul 4;17(10):1443-9 [12824781.001]

(PMID = 20710013.001).

[ISSN] 1468-330X

[Journal-full-title] Journal of neurology, neurosurgery, and psychiatry

[ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry

[Language] eng

[Grant] United States / NINDS NIH HHS / NS / K24 NS 060950; United States / NIAID NIH HHS / AI / R01 NS/AI 041198; United States / NINDS NIH HHS / NS / NS 047029; United States / NINDS NIH HHS / NS / R01 NS041198; United States / NINDS NIH HHS / NS / R01 NS047029; United States / NINDS NIH HHS / NS / K24 NS060950

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Viral

[Other-IDs] NLM/ NIHMS266515; NLM/ PMC3077967

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

A 44-year-old man with relapsed HIV-associated stage IV nodular sclerosing Hodgkin's disease underwent high-dose therapy with autologous stem cell transplantation.

Autologous stem cell transplantation is safe in HIV patients and can achieve long-term durable remissions in Hodgkin's disease.

[MeSH-major] Antiretroviral Therapy, Highly Active. Hematopoietic Stem Cell Mobilization / methods. Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / therapy. Lymphoma, AIDS-Related / therapy

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

MedlinePlus Health Information. consumer health - Hodgkin Disease.

Hazardous Substances Data Bank. LOMUSTINE .

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18301069.001).

[ISSN] 1473-5571

[Journal-full-title] AIDS (London, England)

[ISO-abbreviation] AIDS

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-associated non-Hodgkin's lymphoma: how much do we know?

[MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentOn] Indian J Cancer. 2010 Jan-Mar;47(1):35-9 [20071788.001]

(PMID = 20071782.001).

[ISSN] 1998-4774

[Journal-full-title] Indian journal of cancer

[ISO-abbreviation] Indian J Cancer

[Language] eng

[Publication-type] Comment; Editorial

[Publication-country] India

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Epstein-Barr virus DNA in serum in a HIV-infected patient during development and treatment of non-Hodgkin's lymphoma.

Immunocompromised patients are at risk of developing Epstein-Barr virus (EBV)-related lymphoproliferative disorders.

Quantitative determination of serum EBV DNA permits early diagnosis of an AIDS-related non-Hodgkin's lymphoma, and surveillance of treatment response and/or relapse, and thus may be a useful tool to monitor disease activity.

[MeSH-major] DNA, Viral / blood. HIV Infections / virology. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

Zurich Open Access Repository and Archive. Full text from .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15965829.001).

[ISSN] 1424-7860

[Journal-full-title] Swiss medical weekly

[ISO-abbreviation] Swiss Med Wkly

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Switzerland

[Chemical-registry-number] 0 / Anti-HIV Agents; 0 / DNA, Viral; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.

Kaposi sarcoma-associated herpesvirus (KSHV) is known to be associated with two distinct lymphoproliferative disorders: primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD)/MCD-associated plasmablastic lymphoma.

We here report a high incidence of KSHV infection in solid HIV-associated immunoblastic/plasmablastic non-Hodgkin's lymphomas (NHLs), in patients lacking effusions and without evidence of (prior) MCD.

Within a cohort of 99 HIV-related NHLs, 10 cases were found to be KSHV positive on the basis of immunostaining for KSHV LNA-1 as well as KSHV-specific polymerase chain reaction.

Our results indicate that KSHV infection is not restricted to PEL and MCD; it is also common (38%) in HIV-related solid immunoblastic/plasmablastic lymphomas.

[MeSH-major] Giant Lymph Node Hyperplasia / virology. HIV Infections / virology. Herpesviridae Infections / virology. Herpesvirus 8, Human. Lymphoma, AIDS-Related / virology. Lymphoma, Large B-Cell, Diffuse / virology. Sarcoma, Kaposi / virology

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15744337.001).

[ISSN] 0887-6924

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS.

We used the San Diego/Orange County cancer registry to identify 64 cases of systemic non-Hodgkin's lymphoma (NHL) with AIDS who received highly active antiretroviral therapy (HAART) at the time of NHL diagnosis or thereafter and 64 NHL controls without AIDS, matched on age, sex, race, time of NHL diagnosis (1994-1995 and 1996-1999), and hospital type (academic, large community, and small community).

Patients with AIDS-related NHL who received HAART had high grade histology and baseline cytopenia and received reduced-dose chemotherapy more often than patients without AIDS.

However, AIDS patients who received HAART and chemotherapy had survival similar to NHL patients without AIDS, an improvement from the pre-HAART era.

Appropriate hematologic support, through growth factors, transfusions, and avoidance of drugs with hematologic toxicity, might allow full dosing of chemotherapy, and perhaps would further improve outcomes among patients with AIDS and NHL.

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17064995.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Grant] United States / NCI NIH HHS / CA / 1K07 CA 096480

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.

PURPOSE: To evaluate the safety and efficacy of rituximab adjunction to the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma.

PATIENTS AND METHODS: HIV-seropositive patients with high-grade lymphoma of B-cell origin were eligible if they had no more than one of the following characteristics: CD4 cell count less than 100/microL, prior AIDS, or performance status less than 2.

Characteristics of patients were median age, 41 years; median CD4 cells, 172/microL; histology, diffuse large B-cell lymphoma (n = 42), immunoblastic (n = 2), Burkitt lymphoma (n = 16), and plasmablastic (n = 1); 42 patients with stage III to IV; International Prognostic Index 0 to 1 (n=31), and 2 to 3 (n = 27).

Eighteen patients died: 16 as a result of lymphoma, one as a result of infection, and one as a result of encephalitis.

CONCLUSION: Rituximab adjunction to CHOP produced a CR rate of 77% and a 2-year survival rate of 75% in patients with AIDS-related non-Hodgkin's lymphoma, without increasing the risk of life-threatening infections.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Hodgkin Disease.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e6 [17308260.001]

[CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e7 [17308261.001]

(PMID = 16896005.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.

OBJECTIVE: To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with AIDS-related non-Hodgkin's lymphoma.

METHODS: The study included 91 patients with AIDS-related non-Hodgkin's lymphoma from the Swiss HIV Cohort Study enrolled between January 1997 and October 2003, excluding lymphomas of the brain.

We extracted AIDS-related non-Hodgkin's lymphoma- and HIV-specific variables at the time of lymphoma diagnosis as well as treatment changes over time from charts and from the Swiss HIV Cohort Study database.

The effect of cART interruptions on AIDS-related non-Hodgkin's lymphoma prognosis remains unclear, however, hepatitis C seropositivity emerged-as a predictor of death beyond the well-known international prognostic index score and CD4+ T-cell count.

[MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17926647.001).

[ISSN] 1359-6535

[Journal-full-title] Antiviral therapy

[ISO-abbreviation] Antivir. Ther. (Lond.)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.

BACKGROUND: Only a few types of cancer are recognised as being directly related to immune deficiency in people with HIV/AIDS.

Our aim was to compare cancer incidence in population-based cohort studies of people with HIV/AIDS and people immunosuppressed after solid organ transplantation.

FINDINGS: Seven studies of people with HIV/AIDS (n=444,172) and five of transplant recipients (n=31 977) were included.

Most of these were cancers with a known infectious cause, including all three types of AIDS-defining cancer, all HPV-related cancers, as well as Hodgkin's lymphoma (HIV/AIDS meta-analysis SIR 11.03, 95% CI 8.43-14.4; transplant 3.89, 2.42-6.26), liver cancer (HIV/AIDS 5.22, 3.32-8.20; transplant 2.13, 1.16-3.91), and stomach cancer (HIV/AIDS 1.90, 1.53-2.36; transplant 2.04, 1.49-2.79).

Infection-related cancer will probably become an increasingly important complication of long-term HIV infection.

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Organ Transplantation.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Lancet. 2007 Jul 7;370(9581):6-7 [17617251.001]

(PMID = 17617273.001).

[ISSN] 1474-547X

[Journal-full-title] Lancet (London, England)

[ISO-abbreviation] Lancet

[Language] eng

[Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Number-of-references] 30

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Autologous stem-cell transplantation in patients with HIV-related lymphoma.

PURPOSE: Peripheral-blood autologous stem-cell transplantation (ASCT) in patients with HIV-related lymphoma (HIV-Ly) has been reported as a safe and useful procedure.

RESULTS: Since 1999, 68 patients from 20 institutions (median age, 41 years; range, 29 to 62 years) were included, diagnosed with non-Hodgkin's lymphoma (NHL; n = 50) or Hodgkin's lymphoma (n = 18).

CI of relapse was 30.4% at 24 months, statistically related with not being in CR at ASCT (relative risk [RR] = 3.6), NHL histology other than diffuse large B-cell lymphoma (RR = 3.4), and use of more than two previous treatment lines (RR = 3).

CONCLUSION: Similarly to HIV-negative patients with lymphoma, ASCT is a useful treatment for patients with HIV-Ly and is associated with low NRM, mainly when performed in early stages and chemo-S disease.

[MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy

Genetic Alliance. consumer health - Transplantation.

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] J Clin Oncol. 2009 Jul 1;27(19):3263

(PMID = 19332732.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States